We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 12 april 2018

Nature Reviews Cardiology - Table of Contents alert Volume 15 Issue 5

If you are unable to see the message below, click here to view.
Nature Reviews Cardiology

Do you have a career question? 

The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. 

Listen today!
May 2018 Volume 15 Number 5
Nature Reviews Cardiology cover
2016 2-year Impact Factor 14.299 Journal Metrics 2-year Median 10
In this issue
Research Highlights
News and Views
Also this month
 Featured article:
Nitric oxide signalling in cardiovascular health and disease
Charlotte Farah, Lauriane Y. M. Michel & Jean-Luc Balligand


Recommend to library
Nature Milestone: Anticoagulants from Nature Reviews Cardiology

This Milestone plots the history of anticoagulant drugs, used to prevent and treat thrombotic disorders in millions of patients worldwide. Fourteen Milestone articles are presented on an interactive timeline with associated multimedia.

Access free online >>

Produced with support from 
Portola Pharmaceuticals, Inc. 

Regeneration: Mending broken hearts
Published online: 22 March 2018
p253 | doi:10.1038/nrcardio.2018.30

The polyploidy of mammalian cardiomyocytes is a barrier to heart regeneration, but modification of the cardiomyocyte cell cycle can boost their regenerative potential.

Basic research: Visceral adipose tissue regulates cardiac ageing
Published online: 22 March 2018
p254 | doi:10.1038/nrcardio.2018.29


Vascular disease: Reduction in major adverse limb events in the COMPASS trial
Published online: 29 March 2018
p254 | doi:10.1038/nrcardio.2018.34


Cardioprotection: SGLT2 blockers in T2DM
Published online: 29 March 2018
p255 | doi:10.1038/nrcardio.2018.35


Developmental biology: Early heart decisions
Published online: 29 March 2018
p256 | doi:10.1038/nrcardio.2018.36


Coronary artery disease: Mortality after CABG surgery versus PCI
Published online: 15 March 2018
p257 | doi:10.1038/nrcardio.2018.24


Inflammation: NETs are involved in AAA
Published online: 15 March 2018
p257 | doi:10.1038/nrcardio.2018.28


Hypertension: Hypertension intervention at the barbershop
Published online: 29 March 2018
p257 | doi:10.1038/nrcardio.2018.37




Hypertension: Benefit of BP self-monitoring for hypertension | Heart failure: BMP9 is an inhibitor of cardiac fibrosis | Inflammation: Pericardial adipose tissue regulates granulopoiesis | Device therapy: Superiority of a centrifugal-flow cardiac pump | Diabetes: No benefit of canakinumab in diabetes prevention | Antiplatelet therapy: Pharmacogenomic approach to tailor drug therapy

Dyslipidaemia: In vivo genome editing of ANGPTL3: a therapy for atherosclerosis?
June-Wha Rhee & Joseph C. Wu

Published online: 05 April 2018
p259 | doi:10.1038/nrcardio.2018.38

Hyperlipidaemia is an important risk factor for coronary artery disease. Chadwick and colleagues report significantly reduced blood lipid levels following CRISPR-based in vivo genome editing in mice to introduce loss-of-function mutations in Angptl3, encoding a lipoprotein lipase inhibitor. Treatment was effective in both wild-type and Ldlr -/- mice and had a similar effect to that of Pcsk9-targeted genome editing, without causing off-target mutations.
Full Text | PDF

Searching for a new career?

At Nature Research we frequently recruit talented individuals to join our editorial and publishing teams. If you have a PhD and a passion for science this may be the perfect career for you. 

Visit our research editorial and publishing careers website to discover more about what we do
Advances in lipid-lowering therapy through gene-silencing technologies
Børge G. Nordestgaard et al.

Published online: 08 February 2018
p261 | doi:10.1038/nrcardio.2018.3

Novel antisense oligonucleotide and small interfering RNA technology can be used to reduce levels of lipoproteins that cause cardiovascular disease. In this Review, Nordestgaard and colleagues describe the principles of these gene-silencing approaches and summarize the trials that have tested the efficacy of these approaches in patients at risk of cardiovascular disease.
Abstract | Full Text | PDF

Reversal agents for non-vitamin K antagonist oral anticoagulants
Jerrold H. Levy, James Douketis & Jeffrey I. Weitz

Published online: 18 January 2018
p273 | doi:10.1038/nrcardio.2017.223

The non-vitamin K antagonist oral anticoagulants (NOACs) include direct inhibitors of factor Xa or thrombin. In this Review, Levy and colleagues describe the mechanism of action of the NOAC-reversal strategies, provide guidance on potential indications for reversal, and offer a management approach for patients treated with NOACs who present with serious bleeding or require urgent surgery.
Abstract | Full Text | PDF

Effect of glucose-lowering therapies on heart failure
Michael Nassif & Mikhail Kosiborod

Published online: 25 January 2018
p282 | doi:10.1038/nrcardio.2017.211

Heart failure has emerged as the most common cardiovascular complication among patients with type 2 diabetes mellitus. In this Review, Nassif and Kosiborod describe the detrimental, neutral, or even beneficial effects of different classes of glucose-lowering medications on heart failure outcomes.
Abstract | Full Text | PDF

Nitric oxide signalling in cardiovascular health and disease
Charlotte Farah, Lauriane Y. M. Michel & Jean-Luc Balligand

Published online: 01 February 2018
p292 | doi:10.1038/nrcardio.2017.224

Nitric oxide (NO) signalling has pleiotropic roles in biology and a crucial function in cardiovascular homeostasis. In this Review, Balligand and colleagues summarize the updated paradigms on NO synthase regulation, NO interaction with reactive oxidant species in specific subcellular compartments, and downstream effects of NO in target cardiovascular tissues under both physiological and pathological conditions.
Abstract | Full Text | PDF | Supplementary information

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
Nature Reviews Cardiology was previously published as Nature Clinical Practice Cardiovascular Medicine.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature